Synlett 2010(13): 1923-1926  
DOI: 10.1055/s-0030-1258489
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

Synthesis of Arylated Pyrazoles by Site-Selective Suzuki-Miyaura Reactions of Tribromopyrazoles

Rasheed Ahmad Kheraa, Asad Alia, Munawar Hussaina, Jovana Tatara, Alexander Villingera, Peter Langer*a,b
a Institut für Chemie, Universität Rostock, Albert Einstein Str. 3a, 18059 Rostock, Germany
Fax: +49(381)4986412; e-Mail: peter.langer@uni-rostock.de;
b Leibniz-Institut für Katalyse an der Universität Rostock e.V., Albert Einstein Str. 29a, 18059 Rostock, Germany
Further Information

Publication History

Received 31 March 2010
Publication Date:
09 July 2010 (online)

Abstract

The first Suzuki-Miyaura reactions of N-protected tribromopyrazoles are reported. Their reaction with three, two, or one equivalents of arylboronic acids afforded 3,4,5-triarylpyrazoles, 3,5-diaryl-4-bromopyrazoles, or 5-aryl-3,4-dibromopyrazoles, respectively. All reactions proceeded with very good site-selectivity.

    References and Notes

  • 1a van Herk T. Brussee J. van den Nieuwendijk AMCH. van der Klein PAM. Ijzerman AP. Stannek C. Burmeister A. Lorenzen A. J. Med. Chem.  2003,  46:  3945 
  • 1b Varano F. Catarzi D. Colotta V. Filacchioni G. Galli A. Costagli C. Carlà V. J. Med. Chem.  2002,  45:  1035 
  • 1c Clayden J. Geeves N. Warren S. Organic Chemistry   Oxford University Press; Oxford: 2000. 
  • 1d Dannhardt G. Laufer S. Curr. Med. Chem.  2000,  71101 
  • 1e Carty TJ. Marfat A. Curr. Opin. Anti-Inflamm. Immunomod. Invest. Drugs  1999,  1:  89 
  • 1f Nicolaou KC. Pratt BA. Arseniyadis S. Wartmann M. O’Brate A. Giannakakou P. ChemMedChem  2006,  1:  41 
  • 2a The Chemistry of Heterocyclic Compounds   Part 1, Vol. 49:  Grunanger P. Vita-Finzi P. John Wiley; New York: 1991. 
  • 2b Aggarwal VK. de Vincente J. Bonnert RV. J. Org. Chem.  2003,  68:  5381 
  • 2c Deng X. Mani NS. Org. Lett.  2006,  8:  3505 
  • 3a Handbook of Heterocyclic Chemistry   Katritzky AR. Pozharskii AF. Pergamon; Oxford: 2000. 
  • 3b Heller ST. Natarajan SR. Org. Lett.  2006,  8:  2675 
  • 3c Humphries PA. Finefield JM. Tetrahedron Lett.  2006,  47:  2443 
  • 3d Bishop BC. Synthesis  2004,  43 
  • 3e Ahmed SM. Kobayashi K. Mori A. Org. Lett.  2005,  7:  4487 
  • For a review of cyclization reactions of dianions in organic synthesis, see:
  • 4a Langer P. Freiberg W. Chem. Rev.  2004,  104:  4125 
  • For original papers, see:
  • 4b Matsumura N. Kunigihara A. Yoneda S. Tetrahedron Lett.  1983,  24:  3239 
  • 4c Matsumura N. Kunigihara A. Yoneda S. Tetrahedron Lett.  1984,  25:  4529 
  • 4d Duncan DC. Trumbo TA. Almquist CD. Lentz TA. Beam CF. J. Heterocycl. Chem.  1987,  24:  555 
  • 4e Beam CF. Reames DC. Harris CE. Dasher IW. Hollinger WM. Shealy NL. Sandifer RM. Perkins M. Hauser CR. J. Org. Chem.  1975,  40:  514 
  • 4f Persson T. Nielsen J. Org. Lett.  2006,  8:  3219 
  • 4g Dang TT. Dang TT. Reinke H. Fischer C. Langer P. Tetrahedron  2008,  64:  2207 
  • 5 Ranatunge RR. Augustyniak M. Bandarage UK. Earl RA. Ellis JL. Garvey DS. Janero DR. Letts LG. Martino AM. Murty MG. Richardson SK. Schroeder JD. Shumway MJ. Tam SW. Trocha AM. Young DV. J. Med. Chem.  2004,  47:  2180 
  • For reviews of cross-coupling reactions of polyhalogenated heterocycles, see:
  • 6a Schröter S. Stock C. Bach T. Tetrahedron  2005,  61:  2245 
  • 6b Schnürch M. Flasik R. Khan AF. Spina M. Mihovilovic MD. Stanetty P. Eur. J. Org. Chem.  2006,  3283 
  • For studies from our laboratory, see:
  • 7a Dang TT. Dang TT. Ahmad R. Reinke H. Langer P. Tetrahedron Lett.  2008,  49:  1698 
  • 7b Dang TT. Villinger A. Langer P. Adv. Synth. Catal.  2008,  350:  2109 
  • 7c Hussain M. Nguyen TH. Langer P. Tetrahedron Lett.  2009,  50:  3929 
  • 7d Tengho Toguem S.-M. Hussain M. Malik I. Villinger A. Langer P. Tetrahedron Lett.  2009,  50:  4962 
  • 7e Dang TT. Dang TT. Rasool N. Villinger A. Langer P. Adv. Synth. Catal.  2009,  351:  1595 
  • 8 Iddon B. Toender JE. Hosseini M. Begtrup M. Tetrahedron  2007,  63:  56 
  • For pharmacologically relevant 3,4,5-triarylpyrazoles, see:
  • 9a Meanwell NA. Rosenfeld MJ. Wright JJK. Brassard CL. Buchanan JO. J. Med. Chem.  1992,  35:  389 
  • For pharmacological relevant 3,5-diaryl-4-bromo-pyrazoles, see:
  • 9b Bondavalli F. Bruno O. Ranise A. Schenone P. Donnoli D. Farmaco  1989,  44:  655 
  • 9c Bondavalli F. Bruno O. Ranise A. Schenone P. Addonizio P. Farmaco  1988,  43:  725 
  • Only very few 5-aryl-3,4-dibromopyrazoles have been reported so far:
  • 9d Trofimenko S. Yap GPA. Jove FA. Claramunt RM. Garcia MA. Santa Maria MD. Alkorta I. Elguero J. Tetrahedron  2007,  63:  8104 
  • 10 Grandberg A. J. Gen. Chem. USSR (Engl. Transl.)  1963,  33:  503 ; Zh. Obshch. Khim. 1963, 33, 511
  • 13 Billingsley K. Buchwald SL. J. Am. Chem. Soc.  2007,  129:  3358 ; and references cited therein
11

General Procedure for Suzuki-Miyaura Coupling Reactions
To a 1,4-dioxane solution (4 mL) of 2a,b (152 mg, 0.5 mmol) was added Pd(PPh3)4 (3-10 mol%) at 20 ˚C under argon atmosphere. After stirring for 30 min, the arylboronic acid (1.0-1.2 equiv per bromine atom of the substrate), K3PO4 (1.5 equiv per bromine atom of the substrate), and H2O (1.0 mL) were added. The mixture was heated for 12 h at 100 ˚C. After cooling to 20 ˚C, the mixture was diluted with H2O, extracted with CH2Cl2 (3 × 25 mL), dried (Na2SO4), and filtered. The solvent of the filtrate was concentrated in vacuo and the residue was purified by column chromatography (heptanes-EtOAc).

12

3,4-Dibromo-5-(4-methoxyphenyl)-1-vinyl-1 H -pyrazole (4c)
Starting with 2b (165 mg, 0.50 mmol), Pd(PPh3)4 (18 mg, 3 mol%), 1,4-dioxane-H2O (4:1, 5 mL), K3PO4 (159 mg, 0.75 mmol), and 4-methoxyphenylboronic acid (76 mg, 0.50 mmol), 4c was isolated as a white solid (131 mg, 73%). ¹H NMR (300 MHz, CDCl3): δ = 3.80 (s, 3 H, OCH3), 4.77 (d, 1 H, J = 8.7 Hz, vinyl), 5.72 (d, 1 H, J = 15.2 Hz, vinyl), 6.70 (dd, 1 H, J = 15.2, 8.7 Hz vinylic CH), 6.95 (d, 2 H, J = 8.8 Hz, ArH), 7.25 (d, 2 H, J = 8.8 Hz, ArH). ¹³C NMR (75.5 MHz, CDCl3): δ = 55.4 (OCH3), 98.2 (C), 102.7 (CH2), 114.3 (CH), 119.0 (C), 129.7 (CH), 130.5 (C), 131.5 (CH), 142.4, 160.7 (C). IR (KBr): 3002, 2936, 2835, 1730 (w), 1641 (m), 1574 (w), 1488 (s), 1432 (m), 1392 (w), 1355 (m), 1332 (s), 1290 (m), 1249 (s), 1196 (w), 1174 (s), 1110 (m), 1030, 984 (s), 888 (m), 833 (s), 801 (m), 725 (w), 602 (m), 551 (m) cm. GC-MS (EI, 70 eV): m/z (%) = 358 (Br, 100) [M]+, 343 (13), 327 (22), 277 (39), 246 (22), 198 (23). HRMS (EI, 70 eV): m/z calcd for C12H10N2Br2O [M]+ (79Br): 355.91544; found: 355.91535.

14

4-Bromo-3,5-bis(4-methoxyphenyl)-1-vinyl-1 H -pyrazole (5a)
Starting with 2b (165 mg, 0.50 mmol), Pd(PPh3)4 (29 mg, 5 mol%), 1,4-dioxane-H2O (4:1, 5 mL), K3PO4 (318 mg, 1.5 mmol), and 4-methoxyphenylboronic acid (152 mg, 1.0 mmol), 5a was isolated as a white crystalline solid (115 mg, 60%). ¹H NMR (300 MHz, CDCl3): δ = 3.79 (s, 3 H, OCH3), 3.81 (s, 3 H, OCH3), 4.75 (d, 1 H, J = 8.5 Hz, vinyl), 5.75 (d, 1 H, J = 15.4 Hz, vinyl), 6.78 (dd, 1 H, J = 8.8, 15.3 Hz, vinylic CH), 6.92 (d, 2 H, J = 8.9 Hz, ArH), 6.96 (d, 2 H, J = 8.8 Hz, ArH), 7.30 (d, 2 H, J = 8.8 Hz, ArH), 7.86 (d, 2 H, J = 8.9 Hz, ArH). ¹³C NMR (75.5 MHz, CDCl3): δ = 55.3, 55.4 (OCH3), 94.2 (C), 101.6 (CH2), 113.7, 114.2 (CH), 120.1, 124.5 (C), 129.4 (CH), 130.3, 131.7 (CH), 142.2, 149.3, 159.9, 160.4 (C). IR (KBr): 3090, 2996, 2834, 1789 (w), 1638 (m), 1574 (w), 1489 (s), 1436 (m), 1307 (w), 1207 (m), 1250, 1178 (s), 1161, 1111 (m), 1029 (s), 1114 (m), 975 (s), 943 (m), 834 (s), 795 (w), 736 (m), 635 (w), 528 (m) cm. GC-MS (EI, 70 eV): m/z (%) = 384 (79Br, 3) [M]+, 365 (8), 332 (7), 281 (13), 207 (100), 175 (09), 135 (04) cm. HRMS (EI, 70 eV): m/z calcd for C19H17N2BrO2 [M]+ (79Br): 384.04734; found: 384.04711.

15

CCDC-777244 contains all crystallographic details of this publication which are available free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html or can be ordered from the following address: Cambridge Crystallographic Data Centre, 12 Union Road, GB-Cambridge CB21EZ; fax: +44 (1223)336033; or deposit@ccdc.cam.ac.uk.

16

3,4,5-Tris(3,5-dimethylphenyl)-1-vinyl-1 H -pyrazole (6f)
Starting with 2b (165 mg, 0.50 mmol), Pd(PPh3)4 (58 mg, 10 mol%), 1,4-dioxane-H2O (4:1, 5 mL), K3PO4 (477 mg, 2.25 mmol), and 3,5-dimethylphenylboronic acid (263 mg, 1.75 mmol), 6f was isolated as a white solid (165 mg, 74%). ¹H NMR (300 MHz, CDCl3): δ = 2.06 (s, 6 H, 2 CH3), 2.10 (s, 6 H, 2 CH3), 2.15 (s, 6 H, 2 CH3), 4.69 (d, 1 H, J = 8.7 Hz, vinyl), 5.78 (d, 1 H, J = 15.3 Hz, vinyl), 6.61-6.90 (m, 8 H), 7.09 (br s, 2 H, ArH). ¹³C NMR (75.5 MHz, CDCl3): δ = 21.1, 21.2, 21.3 (CH3), 100.5 (CH2), 120.5 (C), 126.2, 128.1, 128.2, 128.5 (CH), 129.2 (C), 129.3, 130.3, 130.4 (CH), 132.6, 133.0, 137.0, 137.4, 137.8, 141.8, 150.4 (C). IR (KBr): 3002, 2915, 2859 (w), 1738, 1642 (m), 1600 (s), 1550 (w), 1444 (m), 1373 (s), 1303, 1268 (w), 1237 (s), 1203, 1154, 1110, 1096 (w), 1093 (m), 996, 900, 881 (w), 848 (s), 789 (w), 691 (m), 542 (w) cm. GC-MS (EI, 70 eV): m/z (%) = 406 (100) [M]+, 391 (26), 375 (2), 259 (4), 203 (3), 180 (2), 132 (4). HRMS (EI, 70 eV): m/z calcd for C29H30N2 [M]+: 406.24090; found: 406.24057.